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Introduction: Perioperative Ischaemic Evaluation-2
(POISE-2) is an international 2×2 factorial randomised
controlled trial of low-dose aspirin versus placebo and
low-dose clonidine versus placebo in patients who
undergo non-cardiac surgery. Perioperative aspirin
(and possibly clonidine) may reduce the risk of
postoperative acute kidney injury (AKI).
Methods and analysis: After receipt of grant
funding, serial postoperative serum creatinine
measurements began to be recorded in consecutive
patients enrolled at substudy participating centres. With
respect to the study schedule, the last of over 6500
substudy patients from 82 centres in 21 countries were
randomised in December 2013. The authors will use
logistic regression to estimate the adjusted OR of AKI
following surgery (compared with the preoperative
serum creatinine value, a postoperative increase
≥26.5 μmol/L in the 2 days following surgery or an
increase of ≥50% in the 7 days following surgery)
comparing each intervention to placebo, and will report
the adjusted relative risk reduction. Alternate definitions
of AKI will also be considered, as will the outcome of
AKI in subgroups defined by the presence of
preoperative chronic kidney disease and preoperative
chronic aspirin use. At the time of randomisation, a
subpopulation agreed to a single measurement of
serum creatinine between 3 and 12 months after
surgery, and the authors will examine intervention
effects on this outcome.
Ethics and dissemination: The authors were
competitively awarded a grant from the Canadian
Institutes of Health Research for this POISE-2 AKI
substudy. Ethics approval was obtained for additional
kidney data collection in consecutive patients enrolled
at participating centres, which first began for patients
enrolled after January 2011. In patients who provided
consent, the remaining longer term serum creatinine
data will be collected throughout 2014. The results of
this study will be reported no later than 2015.
Clinical Trial Registration Number:
NCT01082874.
BACKGROUND
Worldwide, an estimate of 200 million adults
have major non-cardiac surgery each year.1
About 10% of patients develop acute kidney
Strengths and limitations of this study
▪ International recruitment of over 6500 patients
across 82 centres in 21 countries will provide
generalisable estimates of the treatment effects
on acute kidney injury (AKI).
▪ The kidney data collection schedule in this large
international trial is feasible and efficient.
▪ Additional studies of the effects of aspirin in the
surgical setting can consider multiple measures
of kidney function over time, both before and
long after AKI, examine long-term trajectories of
kidney function loss and new markers of kidney
function or injury.
Garg AX, Kurz A, Sessler DI, et al. BMJ Open 2014;4:e004886. doi:10.1136/bmjopen-2014-004886 1
Open Access Protocol
injury (AKI) (defined by an acute rise in serum creatin-
ine of 50% or more or an acute rise of 26 μmol/L or
more), and 0.5% receive acute dialysis.2 In other words,
worldwide there are several million annual cases of AKI
attributable to major non-cardiac surgery, with about a
million cases receiving acute dialysis. When AKI occurs
(versus when it does not), it is associated with increased
mortality, longer hospital length of stay and higher
healthcare costs.3–5 Treatments to prevent the onset of
AKI or its complications remain elusive.6
The major mechanism of perioperative AKI is
impaired kidney perfusion and ischaemia. Activation of
inflammatory mediators, adhesion molecules, platelets
and thromboxane is thought to be involved in the injury
(figure 1).7 8
In the surgical setting, aspirin prevents platelet aggre-
gation and may improve glomerular blood flow. In
online supplementary appendix 1, we provide three
lines of evidence to support the hypothesis that peri-
operative aspirin use reduces the risk of postoperative
AKI.7–15 The pathways where aspirin may mitigate AKI
are presented in figure 1.16
We are conducting the Perioperative Ischaemia
Evaluation-2 trial (POISE-2). The methods of this large,
international 2×2 factorial randomised placebo con-
trolled trial are described elsewhere (available from the
authors on request).17 In brief, adults at moderate and
high risk for postoperative cardiac events are randomly
allocated to receive either aspirin or matching placebo,
and clonidine or matching placebo. Eligible surgeries
are those where a patient is expected to stay for at least
one night in the hospital after surgery. The aspirin inter-
vention is 100 mg tablets of aspirin or matching placebo,
where patients take two tablets orally 2–4 h prior to
surgery, and then take one tablet daily for either 7 or
30 days (depending on whether they were taking aspirin
chronically prior to surgery or not, respectively). The
clonidine intervention consists of 0.2 mg of oral cloni-
dine or matching placebo given 2–4 h prior to surgery,
and at the same time a transdermal clonidine or
placebo patch is applied for 72 h, providing clonidine at
0.2 mg/day. Allocation is performed by a central ran-
domisation service and is stratified by the centre.
Patients, healthcare providers, data collectors and
outcome adjudicators are blinded to treatment alloca-
tion. This trial is primarily funded by the Canadian
Institutes of Health Research. With respect to the study
schedule, the last of 10 000 patients from 140 centres in
23 countries was randomised in December 2013. The
primary outcome is a composite of 30 day all-cause mor-
tality or non-fatal myocardial infarction. The secondary
outcome is a composite of 30 day all-cause mortality,
non-fatal myocardial infarction and non-fatal stroke.
In addition to the primary outcome, POISE-2 is
uniquely positioned to determine the effects of peri-
operative aspirin (and clonidine) on AKI, to consider
whether treatment effects on AKI differ in those with
preoperative chronic kidney disease (CKD) and
preoperative chronic aspirin use, and to investigate the
treatment effects on longer term kidney function, based
on a single measurement taken 3 months to 1 year after
surgery. We were awarded an additional grant from the
Canadian Institutes of Health Research to examine
these issues in a POISE-2 AKI substudy. The AKI ques-
tions detailed in the grant are presented below and are
followed by our prespecified analytic plan.
Primary question
1. In patients undergoing non-cardiac surgery, does the
use of aspirin at the time of surgery compared with
placebo alter the risk of postoperative AKI? Is the
treatment effect (the observed relative risk reduc-
tion) similar across alternate definitions of AKI?
Hypothesis: perioperative aspirin versus placebo at the
time of surgery will reduce the risk of postoperative
AKI, and the treatment effect will appear similar
across alternate definitions of AKI.
Secondary questions
2. Does the observed relative risk reduction of aspirin
versus placebo on postoperative AKI differ in patients
with and without preoperative CKD? Hypothesis: the
relative risk reduction will be greater in patients with
preoperative CKD than in those without CKD (as we
demonstrated in another setting—a large inter-
national randomised trial of coronary artery bypass
surgery performed either with or without a bypass
pump).
3. Does the observed relative risk reduction of aspirin
versus placebo on postoperative AKI differ in patients
who were chronically taking aspirin before surgery,
compared to those who had aspirin initiated at the
time of surgery? Hypothesis: the relative risk reduction
will be greater in the aspirin continuation stratum
than in the aspirin initiation stratum, as there may be
an increased risk of thrombosis after aspirin discon-
tinuation (as observed in some human studies, recog-
nising the biology is complicated).18
4. Does perioperative aspirin versus placebo alter longer
term kidney function (indicated by a single measure
of serum creatinine 3–12 months after surgery)?
Hypothesis: we will be unable to demonstrate a better
outcome with perioperative aspirin versus placebo
due to limitations in the measurement techniques, or
the limited impact of any observed AKI risk reduc-
tion on longer term kidney function.
Other questions
5. In patients undergoing non-cardiac surgery, does the
use of perioperative clonidine at the time of surgery
compared with placebo alter the risk of postoperative
AKI? Hypothesis: perioperative clonidine versus
placebo at the time of surgery will reduce the risk of
postoperative AKI (a notion supported by some
animal and human studies,19–24 recognising that an
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elevated risk of AKI could also manifest from
clonidine-induced hypotension).
POISE-2 DATA COLLECTION AND ANALYTIC PLAN
POISE-2 enrolment began in July 2010, and enrollment
in the POISE-2 AKI substudy began in January 2011. To
refine the analytic plan, we reviewed POISE-2 data as of
April 2013 (when data reconciliation was ongoing and
without any knowledge of patient allocation to the
assigned treatments).
POISE-2 AKI substudy data collection
A preoperative serum creatinine value is measured
within 6 weeks of surgery. The date of surgery (and not
the date of randomisation) is used to identify the start
of follow-up in this protocol; the median (IQR) number
of days between the date of randomisation and the
date of surgery is 0 (0–0; 95th percentile 1 day). After
receipt of grant funding to support this substudy, serial
perioperative serum creatinine data began to be
recorded in consecutive patients enrolled at AKI sub-
study participating centres (earliest centre to start this
process began in January 2011). All centres were encour-
aged to record a serum creatinine value postoperative
days 1, 2 and 3 in consecutively enrolled patients (pro-
vided the patient was not discharged from hospital).
This will help reduce concerns about an ascertainment
bias related to AKI (ie, where aspirin vs placebo alters
the incidence of another event such as myocardial
infarction or bleeding, which in turn influences the like-
lihood of serum creatinine measurement). We also
record all other serum creatinine measurements per-
formed as a part of routine care (and their dates)
during the hospital stay. At the time of final analysis, we
will examine the number of measurements by treatment
group (and the postoperative days of these measure-
ments) to confirm that there is no differential ascertain-
ment of AKI in the two treatment groups.
The median hospital length of stay in POISE-2 is
4 days (IQR 3–7 days). The proportion of patients who
die in the operating room or in 48 h after surgery, which
may result in no serum creatinine measurement, is
expected to be <1% of patients. Less than 10% of
patients are expected to have a missing peak serum cre-
atinine value during the hospital stay, and in such cases,
in the absence of receipt of acute dialysis, we will carry
forward the prerandomisation serum creatinine value
for all analyses (which means the patient will not have
developed AKI; see analysis section). Urine output data
are, however, not collected in POISE-2 given the difficul-
ties with accurate measurement in the setting of inter-
national data collection (and thus a low urine output is
not used to define AKI in POISE-2). Receipt of new dia-
lysis for kidney failure is recorded at hospital discharge
and at 30 days after surgery.
Longer term kidney function measurement
In participating centres, at the time of randomisation,
patients were invited to enrol in a substudy to record a
Figure 1 Mechanism for
development of acute kidney
injury in major non-cardiac
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single longer term serum creatinine value, anytime
between 3 and 12 months after surgery. A measurement
performed at a time when a patient is not acutely ill is
valid.
The additional serum creatinine collection (particu-
larly the longer term creatinine measurement) was
added to the patient consent requests and received
ethical approval at each of the AKI substudy participat-
ing sites.
Patient selection
All patients enrolled in the POISE-2 AKI substudy at the
time of randomisation will be included in the final analysis
except for the following three reasons: (1) those with end-
stage renal disease prior to randomisation (expected <2%
of patients), as the assessment of AKI is no longer relevant
(estimated-glomerular filtration rate (eGFR) <15 mL/
min/1.73 m2 as determined by the CKD-epidemiology col-
laboration equation,25 receipt of chronic dialysis or a base-
line serum creatinine >327 μmol/L (the last exclusion also
enables retained patients to have their new-onset AKI
staged according to most recent guidelines26)), (2) those
missing a pre-randomisation serum creatinine value or
missing age or sex (expected in <3% of patients) as this is
needed to define baseline CKD or subsequent AKI, (3)
those who never underwent surgery (expected in <2% of
patients) as they will not have the opportunity to have any
postoperative serum creatinine measurements. We expect
to enrol over 6500 eligible patients in the POISE-2 AKI
substudy, with a subpopulation of at least 3000 patients
who, at the time of randomisation, agree to the longer
term creatinine measurement.
Intention to treat
The intention-to-treat principle will guide all primary
analyses, irrespective of whether there is a deviation
from the randomly allocated therapy. Currently, <1.5%
of patients in POISE-2 did not receive the study medica-
tion (neither aspirin nor clonidine), 0.1% of patients
received non-study aspirin within 24 h prior to surgery
and 5.2% received non-study aspirin in the first 3 days
after surgery. At the time of final analysis, these results
will be reported by the treatment group.
Primary definition of acute kidney injury
We will use a mixed effects logistic regression model to
obtain an estimate of the OR of AKI comparing aspirin
to placebo (after testing model assumptions; online sup-
plementary appendix 2). While logistic regression
models will be used for hypothesis testing, at the time of
final analysis we will preferentially report relative risk
reductions of aspirin relative to placebo as this metric is
easier to interpret by a clinical audience (and hence we
use relative risk reduction nomenclature throughout this
protocol appreciating that the logistic regression model
produces an OR; the method to derive a relative risk
reduction from an OR is presented in online supple-
mentary appendix 3).27
AKI will be primarily defined as per recent guidelines
as any of the following two criteria: (1) an increase in
serum creatinine ≥26.5 μmol/L within 48 h of surgery or
(2) an increase in serum creatinine ≥50% from baseline
within 7 days of surgery.26 For the primary analysis, we
will treat centre as a random effect and adjust for the fol-
lowing baseline characteristics:28 age (per year), sex,
presence of cardiovascular disease (any coronary artery
disease, peripheral vascular disease or stroke), presence
of diabetes, preoperative eGFR category (>60 mL/min/
1.73 m2 vs ≤60 mL/min/1.73 m2), a history of smoking
within 2 years of surgery, receipt of urgent or emergency
surgery (about 8% of POISE-2 participants), type of
surgery (major vascular surgery, major thoracic surgery,
other surgery), chronic use of aspirin therapy and use of
the following medications in each of two periods prior to
randomisation (7 days to <6 h prior to surgery, and ≤6 h
prior to surgery): COX-2 inhibitor/non-steroidal anti-
inflammatory drugs/non-COX-2 inhibitor, a statin, an
ACE inhibitor/angiotensin receptor blocker/direct
renin inhibitor and use of another antihypertensive
agent (any of the following: a rate controlling calcium
channel blocker, dihydropyridine calcium channel
blocker or a β-blocker). We will also adjust for the
random allocation of clonidine (clonidine versus
placebo). In patients who underwent surgery but are
missing a postoperative serum creatinine value (expected
<10% of patients), we will impute in its place the preran-
domisation serum creatinine value which should provide
a more conservative estimate of the intervention effect
than the alternative of removing such patients. We
expect that <0.5% data will be missing for each variable,
and if missing we will consider the condition to be
absent. We will report the 95% CI of our estimates, and a
two-tailed p value of ≤0.05 will be considered statistically
significant. With a sample of at least 6500 patients, we
will have over 80% power to detect at least a 20% relative
risk reduction in AKI with aspirin versus placebo should
it exist (anticipated incidence of AKI of ∼12% in the
placebo group, two-tailed α=0.05, χ2 test; table 1). For
completeness and interpretation, in the setting of a sig-
nificant adjusted relative risk reduction we will also
report the unadjusted relative risk reduction (with 95%
CI) and the unadjusted absolute risk difference (with
95% CI). A significant unadjusted absolute risk differ-
ence will also be expressed as the ‘number needed to
treat (NNT)’ (1/absolute risk difference; a measure
which indicates how many patients need to receive peri-
operative aspirin to prevent one patient from developing
AKI who otherwise would develop AKI if they receive
placebo; a lower number indicating a greater benefit of
aspirin). The 95% CI of the NNT is the inverse of the
Wald CI for the absolute risk difference.29 30
Alternate definitions of AKI
To determine how robust the AKI results are, we will
examine the effect of aspirin versus placebo on alternate
definitions of AKI. A two-tailed p value ≤0.05 will be
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considered statistically significant in these analyses if
results are concordant with the primary results. The stat-
istical power to detect a 20% relative risk reduction in
each of these outcomes is also presented in table 1. As
seen, there is inadequate statistical power to detect a
clinically important difference in some outcomes (such
as stage 2 AKI); these outcomes will be reported given
their clinical significance and we will visually compare
the point estimates and 95% CI of the relative risk
reduction for each definition of AKI.
▸ AKI or death: A composite outcome of either the
primary AKI definition or death within 48 h of surgery.
This is to account for the potential impact that early
deaths may have on the ascertainment of AKI.
▸ AKI for at least 2 days: Defined by evidence of a ≥50%
or a ≥26.5 μmol/L increase in postoperative serum
creatinine from the preoperative value, evident on at
least two different days within 7 days of surgery. While
the magnitude of the peak change in serum creatin-
ine defines the stage of AKI in recent guidelines, a
longer duration of AKI is also associated with poorer
outcomes.31
▸ Stage 2 AKI or more: Defined as any of the following
three criteria—(1) postoperative percent increase in
serum creatinine ≥100% from the preoperative value
within 7 days of surgery, (2) increase in postoperative
serum creatinine to an absolute value ≥353.6 μmol/L
within 7 days or (3) receipt of acute dialysis within
30 days.
In addition to dichotomous outcomes, we will use a
linear regression model to compare the two groups in
the outcome of percent change in serum creatinine
((peak postoperative serum creatinine (within 7 days of
surgery)—preoperative serum creatinine)/preoperative
serum creatinine), adjusting for the variables described
in the primary outcome analysis (assuming model
assumptions are not violated; testing presented in online
supplementary appendix 2). We will report the result as
the average difference in per cent change in serum cre-
atinine between the two treatment groups with 95% CI.
Subgroup analyses: presence of preoperative CKD and
chronic aspirin use
We will use an interaction term in a mixed effects logis-
tic regression model where centre is treated as a random
effect to determine if the adjusted OR of AKI comparing
aspirin to placebo differs in those with and without CKD
(assuming model assumptions are not violated; testing
presented in online supplementary appendix 2). We will
interpret a two-tailed p value ≤0.05 as statistically signifi-
cant. With 6500 patients, we will have over 80% power to
detect a 45% lower OR of AKI with treatment for
patients with and without CKD (an estimate derived
from our simulations; in another recent large trial of
coronary artery bypass graft surgery performed with and
without a bypass pump, the observed percent decrease
in the OR of AKI was 40% lower in patients with CKD
compared to those without CKD) (p value for inter-
action 0.01). Similar to techniques used for the CKD
subgroup, we will examine subgroups defined by the
presence of preoperative chronic aspirin use (which was
a stratification factor used in the randomisation—aspirin
initiation and aspirin continuation strata). Similarly, we
will have over 80% power to detect a 40% lower OR of
AKI with treatment for patients in the continuation
stratum compared to the initiation stratum. An increased
risk of thrombosis after aspirin discontinuation has been
observed in some human studies, recognising that the
biology is complicated.18
Additional analyses
Longer term kidney function loss after surgery
This analysis will focus on those patients who, at the
time of surgery, consent to a single serum creatinine
measurement between 3 and 12 months after surgery.
For our main analysis, we will use linear regression
adjusting for prior listed covariates to compare the abso-
lute change in eGFR between the aspirin and placebo
groups, reporting the mean and 95% CI (assuming
model assumptions are not violated, online supplemen-
tary appendix 2). We will carry forward the









eGFR ≤60 mL/min/1.73 m2
(n=1190)
Statistical power to
detect a 20% relative
risk reduction
(6500 patients)
AKI (primary definition) 580 (11.9%) 398 (10.8%) 182 (15.3%) 88%
Alternate definitions
AKI or death 583 (12.0%) 399 (10.8%) 184 (15.5%) 88%
AKI for at least 2 days 309 (6.3%) 190 (5.2%) 119 (10.0%) 57%
Stage 2 AKI or more 138 (2.8%) 97 (2.6%) 41 (3.5%) 32%
*Number of POISE-2 AKI substudy patients randomised as of April 2013. By December 2013, we expect over 6500 patients will be enrolled
into the study.
Two-tailed α=0.05, χ2 test, assumes that the incidence observed in all patients (n=4880) will be the incidence observed in the placebo group.
AKI, acute kidney injury; eGFR, estimated-glomerular filtration rate, POISE-2, Perioperative Ischaemic Evaluation-2.
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prerandomisation serum creatinine value for patients
with a missing longer term value after surgery (for
reasons of death or missing measurement) and impute
an eGFR value of 5 mL/min/1.73 m2 for the long-term
measurement for any patient who developed end-stage
renal disease (≥3 months of continuous dialysis), or who
died shortly after receipt of acute dialysis for severe AKI.
A sample of 3000 patients will allow a 5 mL/min/
1.73 m2 or more difference to be detected between the
two groups with over 80% statistical power (two-tailed
α=0.05, independent samples t test, expected SD=40). As
observed in the setting of another international trial of
coronary artery bypass surgery performed with and
without a cardiopulmonary bypass pump, we do not
expect to demonstrate that perioperative aspirin versus
placebo alters this outcome, even in the situation where
we demonstrate aspirin versus placebo reduces the risk
of postoperative AKI (which may relate to our study
methods or the limited impact of any observed AKI risk
reduction on longer term kidney function).
Postoperative cardiac events
Acute cardiac events are inextricably linked to AKI
events and both events often occur together in the non-
operative setting. In the setting where aspirin versus
placebo reduces the risk of AKI, we will also examine
cardiac events in the analysis and report how frequently
both co-occur.
A higher risk of AKI with aspirin
Although we hypothesise that aspirin use will prevent
perioperative AKI, our analysis may also elucidate AKI
harm from aspirin if it exists. Although nephrotoxicity
from non-steroidal anti-inflammatory agents is well
appreciated (through the inhibition of intrarenal prosta-
glandin), aspirin doses of 100 mg/day, as used in
POISE-2, are unlikely to be nephrotoxic.32 However,
bleeding with aspirin is an important concern which can
cause hypotension and AKI.7 33 Similarly, blood transfu-
sions may directly predispose to AKI, possibly through
some haemolysis.34 If we observe that aspirin versus
placebo increases the risk of AKI, then we will examine
bleeding events and AKI and report how frequently they
both co-occur.
Exclusion of major urological surgeries
POISE-2 records surgical types in categories, and one of
these categories is major urological or gynaecological
surgery (about 13% of patients enrolled in POISE-2).
This category includes the procedure of nephrectomy.
Because postoperative changes in serum creatinine in
the context of partial or complete nephrectomy can
occur for reasons other than AKI, in an additional ana-
lysis we will exclude this category of surgery to confirm
that the results on the remaining sample are no differ-
ent than the primary results.
Effects of clonidine on AKI
While our prespecified hypotheses focus on aspirin, it is
conceivable that clonidine may reduce the risk of AKI as
supported by prior animal and human studies.19–24 The
analytic techniques for the assessment of clonidine on
AKI are as specified for aspirin, with only minor adjust-
ments (ie, adjustment for the random allocation to
aspirin and no prespecified subgroup analysis for
chronic aspirin use). If a greater risk of AKI is observed
with clonidine versus placebo, then the blood pressure
data collected in POISE-2 will be reviewed to determine
if this potentially explains the observed effect.
RECOGNISED LIMITATIONS
There are some limitations to our protocol.
Errors with serum creatinine as a measure of kidney
function
In POISE-2, the preoperative serum creatinine is
recorded only once in the 6 weeks prior to surgery
(where patients may be undergoing elective, urgent or
emergent surgery). It would be preferable to have at
least two baseline serum creatinine values on all
POISE-2 patients, separated by at least 3 months, to
more accurately define the presence of CKD. Also, in
POISE-2, there is no knowledge of potential serum cre-
atinine changes close to the time of surgery (particularly
in the case of urgent/emergent surgery; 8% of POISE-2
patients), which may mean that the preoperative serum
creatinine value is not in a steady state. All of these con-
siderations increase ‘noise’ related to the baseline serum
creatinine measurement, and reduce the ability to
detect postoperative changes in the serum creatinine—
to partly address this, we are adjusting for a definition of
urgent/emergent surgery in the primary analysis of
covariance models. Also, in an additional analysis, we
will exclude patients undergoing urgent/elective surgery
to confirm that the findings are robust in the remaining
patients undergoing elective surgery.
Worldwide, over the last decade, there have been
efforts to better standardise the serum creatinine assay.
It seems likely (although not documented in POISE-2)
that most preoperative and postoperative serum creatin-
ine measurements prior to hospital discharge would be
performed in the same laboratory, and most measure-
ments are performed within 2 months of each other.
This reduces concerns about interlaboratory and intrala-
boratory variability (drift) in the serum creatinine meas-
urement. However, the same cannot be said for the
longer term serum creatinine measurement. As with the
preoperative value, multiple serial measures of serum
creatinine over the year (and longer) were desired, but
not possible to obtain in POISE-2. Also, POISE-2 has no
measures of baseline or follow-up proteinuria, which are
now featured in recent CKD staging systems.35 However,
the randomisation and analysis of this substudy is strati-
fied by centre, which should result in similar
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measurement errors within a centre for the aspirin and
placebo groups.
Limited statistical power for the most clinically important
kidney outcomes
Stage 3 AKI with receipt of acute dialysis, and long-term
end-stage renal disease are the most clinically important
kidney outcomes. However, there will be too few events for
adequate statistical power to detect these outcomes in
POISE-2. We focus on mild to moderate AKI (defined by
thresholds of changes in serum creatinine). While
mild-to-moderate AKI is the outcome used in virtually all
prior AKI prevention trials, we recognise that it is a surro-
gate outcome that may not directly impact how a patient
feels, functions or survives. Similarly, the longer term
outcome of between-group difference in change in eGFR is
also a surrogate outcome, and concerns about its validity as
a measure of kidney disease progression have been raised.36
For this reason, the overall POISE-2 trial results (which
focus on non-kidney outcomes), rather than the results of
this AKI protocol, should be the primary information used
to inform decisions about whether the tested interventions
should be adopted as a standard in surgical care.
CONCLUSIONS
Strengths of this POISE-2 AKI protocol and the overall
POISE-2 trial are generalisable estimates derived from
patients recruited in an international context using
rigorous randomised trial methodology (eg, concealed
allocation, placebo-controlled trial, blinded central adju-
dication of outcomes). In this report, we have judiciously
prespecified the main questions and analytic protocol
that will be used to test relevant AKI hypotheses in the
POISE-2 AKI substudy. This protocol will help minimise
the chance of spurious post hoc assertions of effect, so
that the AKI results from this large international are
robust and believable.
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